{"id":"W1972415660","doi":"10.1038/bjc.2014.494","title":"Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study","year":2014,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Gemcitabine; Rash; Pancreatic cancer; Erlotinib Hydrochloride; Internal medicine; Hazard ratio; Adverse effect; Clinical endpoint; Gastroenterology; Oncology; Confidence interval; Cancer; Epidermal growth factor receptor; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002670233,0.0009791319,0.001628557,0.0003741357,0.000234608,0.0007236735,0.0007563845,0.0008744464,0.003494668],"category_scores_gemma":[0.001422666,0.000325082,0.001519555,0.0003664175,0.0008489325,0.0005899972,0.0004271853,0.002529899,0.000566786],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00073812,"about_ca_system_score_gemma":0.001151416,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004461337,"about_ca_topic_score_gemma":0.001216609,"domain_scores_codex":[0.9991444,0.0005792066,0.00003527315,0.0000763576,0.00007949185,0.00008526627],"domain_scores_gemma":[0.9989779,0.0002779382,0.0003577732,0.00008548328,0.00004465072,0.0002563282],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.830619,0.05336865,0.005364418,0.001520962,0.002119462,0.0002171982,0.000305146,0.003618917,0.0238309,0.0003409082,0.002565462,0.07612894],"study_design_scores_gemma":[0.7171066,0.269821,0.006689275,0.00005666626,0.000705449,0.0002124485,0.0000412966,0.0009280025,0.00213005,0.0001566582,0.002124491,0.00002819126],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949008,0.001805187,0.0003324394,0.0003402897,0.00005366697,0.001245041,0.0002548624,0.00004163897,0.001025983],"genre_scores_gemma":[0.9890438,0.002590259,0.001785878,0.0009297344,0.0001839578,0.002766058,0.0008294329,0.00002236252,0.001848453],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003494668,"threshold_uncertainty_score":0.01412171,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05602157314813496,"score_gpt":0.4334477661941996,"score_spread":0.3774261930460646,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}